Teriparatide Acetate is a synthetic polypeptide that consists of the 1-34 amino-acid fragment of human parathyroid hormone, the biologically active N-terminal region. Teriparatide is a recombinant form of parathyroid hormone. CAS No. 52232-67-4(net) Molecular Formula C181H291N55O51S2 Molecular Weight 4117.72.
Teriparatide (Forteo) is a recombinant form of parathyroid hormone, used in the treatment of some forms of osteoporosis. Teriparatide Acetate affects calcium and phosphorus metabolism in a pattern consistent with the known actions of endogenous PTH (i.e., increases serum calcium and decreases serum phosphorous.) Teriparatide Acetate binds to the same receptors as PTH and is known to exert effects identical to that of PTH on the bone and the kidney. The acetate form is given by intravenous infusion in the differential diagnosis of HYPOPARATHYROIDISM and PSEUDOHYPOPARATHYROIDISM. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Parathyroid hormone is secreted by the four parathyroid glands found on or embedded in the two lateral lobes of the thyroid gland. hPTH 1-34 acts on bone to mobilize calcium and on the kidney to reduce calcium clearance, increase phosphate excretion, stimulate the release of cyclic AMP in the urine, and stimulate the conversion of 25-hydroxyvitamin D3(25-OH-D3) to the active form 1, 25-dihydroxyvitamin D3(1,25(OH)2D3).
Teriparatide Acetate is used for the treatment of osteoporosis in men and postmenopausal women and is effective at reducing the incidence of new vertebral and nonvertebral fragility fractures in osteoporotic patients. Unlike other treatments for osteoporosis that primarily reduce bone turnover, Teriparatide Acetate reduces bone turnover, stimulates the formation of new bone, and increases bone mass. Teriparatide Acetate may be an acceptable alternative for the treatment of osteoporosis in patients who have failed other treatment modalities.
More about: Teriparatide Acetate Sale
Read more>> www.polypeptides.net
No comments:
Post a Comment